On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK changes. This approval is based on the Phase III IMpower130 study which showed that Tecentriq in combination with chemotherapy helped people live significantly longer than chemotherapy alone.

This approval offers a new combination therapy option to improve survival for those living with the disease.

Click here to read the full press release.